Get unlimited access to Bruins cup coverage - Just 99¢

The Boston Globe

Business

Boston.com

Alnylam gets orphan status for drug candidate

By Associated Press

 |   

  June 19, 2012

CAMBRIDGE — Alnylam Pharmaceuticals Inc. said Tuesday that it received special regulatory incentives for a drug designed to treat a potentially fatal neurodegenerative disease. Alnylam said its drug candidate ALN-TTR02 received orphan drug status. That means if Alnylam’s drug is approved, competing products won’t be allowed on the market for up to seven years. The Food and Drug Administration grants orphan drug status to therapies that could treat diseases that affect fewer than 200,000 people in the US.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help

  • Phone

    888-MY-GLOBE

    Monday-Friday 6:00 a.m.- 5:00 p.m.

    Saturday, Sunday and Holidays 7:30 a.m.- 12:00 noon

  • Chat

    Start a chat

    Monday-Sunday 8:00 a.m.- 5:00 p.m.

  • E-mail

    support@bostonglobe.com